论文部分内容阅读
前列腺癌是西方男性最常见癌症之一,在癌症死亡率中位居第二。在东方,前列腺癌近年来已呈现明显的上升趋势。前列腺癌的治疗效果,决定于发现的早晚。早期发现和治疗,对延长患者寿命有重要意义。为了能早期发现,美国肿瘤学会建议对美国男性前列腺癌筛查,法国最近的一项研究也支持家族性前列腺癌症者史应进行筛查。前列腺特异抗原(prostate specific antigen,PSA)的检测,已被广泛应用于临床。目前仍认为PSA是筛查前列腺癌的最佳标志物;最近美国研究者又发现一种新的前列腺癌确诊标志物α—甲酰辅酶A消旋酶(A-MACR)。现将二者仍以概要介绍。
Prostate cancer is one of the most common cancers in Western men, ranking second among cancer deaths. In the East, prostate cancer has shown a clear upward trend in recent years. Prostate cancer treatment, decided to find sooner or later. Early detection and treatment, to extend the life of patients is important. For early detection, the American Oncology Society recommends screening for prostate cancer in men in the United States, and a recent French study also supports screening for a history of familial prostate cancer. Prostate specific antigen (PSA) detection, has been widely used in clinical. PSA is still considered the best screening of prostate cancer markers; recently, the United States researchers also found a new diagnostic marker for prostate cancer α-formyl CoA racemase (A-MACR). Now both are still outlined.